Prothrombin complex concentrates

(Redirected from PCC)


  • Type: Hemostatics, blood components
  • Dosage Forms:lypophilized concentrate for reconstitution 500u/vial and 1000u/vial
  • Common Trade Names: Kcentra
  • 3 factor PCC (Factors II, IX, and X), would need to supplement with factor VII for reversal if using 3 factor PCC
    • Approved for treatment of hemophilia B (factor IX deficiency)
  • 4 factor PCC (Factors II, VII, IX, and X)
    • Approved for reversal of vitamin K antagonists
  • Does not require thawing or ABO-compatibility testing, and less risk for volume overload (in contrast to FFP) [1]

Adult Dosing

  • Based on pretreatment INR, units based on factor 9 content
    • INR 2-4: 25units/kg, not to exceed 2500 units
    • INR 4-6: 35units/kg, not to exceed 3500 units
    • INR >6: 50units/kg, not to exceed 5000 units
  • Consider rechecking INR after 15 minutes to determine need for redosing
  • Fixed dose Kcentra equivalent to weight based (while being easier to administer and less expensive)[2][3]
    • Baseline INR ≤7.5 and ≤100 kg: 1500 units of Kcentra
    • Baseline INR >7.5 or >100 kg: 2000 units of Kcentra

Pediatric Dosing

  • Safety and efficacy not established

Special Populations

  • Pregnancy Rating: C
  • Lactation: Unknown, breast feeding not advised
  • Renal Dosing
    • Adult-N/A
    • Pediatric-N/A
  • Hepatic Dosing
    • Adult-N/A
    • Pediatric-N/A


  • Allergy to class/drug
  • DIC
  • known HIT (Heparin induced thrombocytopenia)


  • Patients receiving PCC for reversal of a vitamin K antagonist (Warfarin) due to life-threatening bleeding have a rate of thromboembolism which is similar to the rate in patients who receive Fresh frozen plasma (7.3% v 7.1%).[4]



  • Half-life: 4-60 hours, depending on clotting factor
  • Metabolism:
  • Excretion:
  • Mechanism of Action: 4 factor PCC contains factors II, VII, XI, X, protein C and S

See Also


  1. Clinton J. Coil. “Transfusion Therapy.” Tintinalli’s Emergency Medicine: a Comprehensive Study Guide, by Judith E. Tintinalli et al., 8th ed., McGraw-Hill Education, 2016.
  2. Bitonti MT et al. Prospective Evaluation of a Fixed-Dose 4-Factor Prothrombin Complex Concentrate Protocol for Urgent Vitamin K Antagonist Reversal. J Emerg Med 2019;X(XX).
  3. Fixed-Dose PCC Dosing for Vitamin K Antagonist-Associated Hemorrhage: Is it Safe and Effective? by Kayvan Moussavi
  4. Milling, TJ Jr et al. Thromboembolic events after vitamin K antagonist reversal with 4-factor prothrombin complex concentrate: exploratory analyses of two randomized, plasma-controlled studies. Ann Emerg Med. 2016 Jan;67(1):96-105. PMID: 26094105